CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

Health Insurance Marketplace Dispensing Limits (pharmacy)

Defines quantity and time-based dispensing limits for specific drugs (brand and generic equivalents) under BCBSNM marketplace pharmacy benefits; applies to members whose plans use these limits and to providers/pharmacies dispensing covered medications.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyHealth Insurance Marketplace Dispensing Limits (pharmacy)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionPrescribers and pharmacies must request prior authorization when dispensing quantities beyond the listed per-product limits.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

30-daytypical dispensing period noted

2 Pens/28dbiologic per-prescription example

subject to changedocument status

~20+distinct drug entries (excerpt)

18/tab/30doral triptan cumulative limit

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Dispensing Limits

Adalimumab dispensing limits

Covered when dispensed within the specified quantity limits

Adalimumab product limits: Each listed adalimumab product is covered up to the specified limit (examples: many auto-injector kits and biosimilars limited to 2 pens or syringes per 28 days; some 40 mg/0.8 ml presentations limited to 1 kit per 28 days or 1 kit per 180 days for starter packs).per product per 28 days as listed

Formulation- and pack-specific limits apply

Albuterol dispensing limits

Covered when dispensed within the specified quantity limits and cumulative rules

Albuterol inhaler and nebulizer limits: Albuterol inhalers are covered up to 2 inhalers per 30 days (some entries also limit to 6 packages per 90 days). Nebulizer solutions are covered to the per-strength mL or vial limits shown (examples: 120 vials/30 days; 60 mL/30 days; 375 mL/30 days). When noted, nebulizer QLs are cumulative across strengths.per product per 30 days as listed

Some nebulizer solution limits are cumulative across strengths

Oral triptans

Covered when cumulative monthly maximum is not exceeded

Oral triptans cumulative limit: Oral triptans are covered provided the cumulative total across all oral triptan agents does not exceed 18 tablets per 30 days.<= 18 tablets per 30 days cumulative

Applies across all oral triptan products

Standard dispensing limits

Covered when dispensing quantity is at or below the listed limit for each product

Per-product standard limits: Each product listed in the formulary section is covered up to its specific dispensing limit (e.g., tablets per 30 days, inhalers per 30 days, grams or mLs per 30/90 days). Some topical and inhaled agents include cumulative rules noted alongside the per-item limit.per-item limits as listed

Exceeding these per-period limits may require prior authorization or be denied

Dispensing quantity limits

Coverage is limited to the following dispensing quantities and timeframes

Per-product quantity and timeframe limits: Each product or formulation is covered up to the specified quantity for the stated timeframe (examples include 30 tablets per 30 days, 1–2 pens or syringes per 28 days, 100 mLs per 30 days for many injectable insulins).see individual product entries

Some entries indicate QL cumulative across injectable formulations or across strengths; follow per-product rules.

Dispensing limits (Marketplace)

Products are covered up to the specified dispensing limit; QL may be cumulative across strengths or presentations as noted.

Marketplace per-product dispensing limits: Coverage is limited to the exact per-product dispensing amounts listed in the marketplace formulary (examples: insulin syringes and pen needles limited to 300 units per 30 days cumulative across syringe products; Rebif syringes limited to 12 syringes per 28 days cumulative across strengths; ixekizumab limited to 1 syringe per 28 days).see product entries

Where cumulative QL is specified, quantities across listed strengths/forms count toward the same limit

Dispensing limit enforcement

Coverage is limited by per-product dispensing quantity limits; drugs are designated for brand/generic availability

Dispensing limit enforcement: A claim is covered only up to the listed dispensing limit for the specified product and time period; quantities exceeding the listed limit require prior authorization or may be denied at adjudication. Brand/generic (B/G/BG) designations are shown per product and should be applied in claims processing.product-specific quantity per time period

Examples and cumulative rules provided in product listings (see relevant entries)

Coverage and dispensing limits in this document are applied at the plan level and may not be uniform for all members. Members and providers should verify plan-specific limitations or exclusions by consulting plan materials or calling the number on the back of the member ID card. Some dispensing limits listed may not apply to all members or may vary by state regulation, and some limits may be limited to a 30-day supply depending on the member's benefit plan.

No explicit product exclusions are listed in the provided excerpt. The policy presents per-product dispensing limits (including inhalation solutions and nebulizer strengths) rather than listing specific drugs as excluded from coverage in these chunks.

Coverage is limited by per-product dispensing quantity limits. Examples include 2 inhalers per 30 days for albuterol inhalers and nebulizer solution limits expressed in mLs or vial counts. Where noted, quantity limits may be cumulative across strengths or presentations, meaning different formulations count toward the same cap.

Within the provided excerpts there are no items explicitly denoted as exclusions; the content consistently defines permitted dispensing quantities and cumulative rules rather than listing drugs that are categorically excluded.

Amounts dispensed that exceed the listed per-product limits or stated cumulative caps are outside the standard dispensing allowance and will require additional review or authorization. Claims submitted for quantities beyond the stated limits may be denied or require prior authorization per payer rules.

Some products in the list have no brand available noted; for example, the ipratropium bromide inhalation solution entry states a dispensing limit and explicitly notes "no brand available." This reflects formulation-level listing rather than an exclusion.

Several entries specify cumulative quantity limits that apply across agents or formulations. Examples include topical corticosteroid entries that note a 100 grams per 30 days (or 180 g per 90 days) cumulative rule and other topical/agent groups where switching between products does not reset the shared quantity limit.

Requests for quantities that exceed the documented dispensing limits (per-period or cumulative) are outside the scope of standard coverage and would generally require prior authorization or may be denied. Providers must follow payer processes to request authorization for amounts beyond the listed limits.

Dispensing requests that exceed the numeric per-product limits (for example, more than the stated tablets, vials, mLs, pens or syringes per the defined time period) are subject to non-coverage or denial at claim adjudication unless an approved exception or prior authorization is obtained.

Some quantity limits are enforced cumulatively at the GPI/group level; for instance, the document notes cumulative enforcement for certain agents (example: letermovir cumulative at GPI level). Exceeding these cumulative GPI-level limits may trigger denial absent authorization.

Drug Identifiers and Coding

Provider Actions, Prior Authorization, and Claims Guidance

Prior Authorization

Dispensing limits and prior authorization

Dispensing limits listed in this document are enforced at claim adjudication. If a prescribed quantity exceeds the listed dispensing limit, the claim may be denied or the member may be responsible for the cost beyond the allowed quantity. Exceeding the dispensing limit often requires prior authorization (PA) — providers should submit a PA when requesting quantity beyond the published limit.

Dispensing limits apply per prescription and/or per defined time period (e.g., per 30 days, per 28 days, per 90 days, per 365 days).
Claims exceeding the listed per-Rx vial/pen caps (for example, vials or pens listed with 1–5 units per period) may be rejected at adjudication unless a PA is obtained.
Some dispensing limits are cumulative across agents or formulations (e.g., oral triptans: maximum 18 tablets per 30 days across all agents; topical and injectable cumulative QLs noted).
Quantity limits for starter kits or NDC-specific starter kits are set at the NDC and must be billed using the correct NDC to align with the QL.
Certain agents (for example, antihemophilic factor products) have dosing- and weight-dependent limits; documentation should support the dose and number of vials requested.
Insulin and injectable product limits may be cumulative across injectable formulations (includes pens, vials, pens-per-period caps, and pen needle/syringe cumulative limits).

Background and Policy Scope

Background: These dispensing limits are administrative controls intended to align medication dispensing with FDA-intended use and to manage pharmacy benefit costs. Coverage for each listed product is limited to the specific quantity per prescription or quantity per time period shown (for example, 2 inhalers per 30 days or 1 pen per 28–56 days for certain biologics). When prescriptions exceed the stated limit, the member may still obtain the medication but will be responsible for any amount beyond coverage, and providers should pursue prior authorization per payer procedures if clinical need justifies greater quantities.

Definitions and Terms

inv-102: Dispensing Limit definition

DefinitionQuantity of covered medication per prescription or in a given time period (e.g., per 30 days)

PurposeDispensing limits encourage medication use as intended and manage benefit costs

Plan varianceSome limits may not apply to all members or may vary by state regulations; verify plan materials or call member ID number

inv-103: QL cumulative across strengths

ConceptQL cumulative across strengths: quantity limit that is cumulative across multiple strengths of the same agent (counts combined toward the cap)

ExampleAlbuterol nebulizer strengths: mL/vial limits are cumulative across strengths when indicated

Per-Product Quantity Limits (Alphabetical Excerpt)

inv-108: abacavir sulfate soln 20 mg/ml (Ziagen)

Productabacavir sulfate soln 20 mg/ml (Ziagen)

Dispensing Limit960 mLs per 30 days

DesignationListed as BG (brand/generic) in source

inv-109: abacavir sulfate tab 300 mg (Ziagen)

Productabacavir sulfate tab 300 mg (Ziagen)

Dispensing Limit60 tablets per 30 days

DesignationListed as BG (brand/generic)

Biosimilars and Related Dispensing Notes

Billing Rule

Use product‑specific limits for Humira and biosimilars

Humira and each adalimumab biosimilar/preparation are assigned individual dispensing limits and coverage flags; ensure the correct product and its listed limit are used for claims/PA.

Each biosimilar/preparation lists its own dispensing limit (e.g., 2 Pens / 28 DAYS).
Coverage designation (B/BG/G) is provided per preparation.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyHealth Insurance Marketplace Dispensing Limits (pharmacy)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionPrescribers and pharmacies must request prior authorization when dispensing quantities beyond the listed per-product limits.

SourceLink

On This Page

Documentation Required

Cumulative dispensing limits

Some dispensing limits described are enforced cumulatively across agents or formulations. Examples: the oral triptan class (maximum 18 tablets per 30 days across all oral triptans), cumulative topical limits (grams or mLs per period across agents), and cumulative QLs across injectable formulations.

Cumulative limits must be documented when requesting an override; specify the total quantity used across agents and the clinical rationale.
Pharmacy claims should reflect the exact units and period used in the QL (units and period must match the QL definition).

Documentation Required

Required claim and documentation alignment

Providers must ensure that the claim line quantity and units match the plan-defined dispensing limit unit and period. When QLs were calculated (for example weight-based biologic dosing or CDC percentile-based vial counts), supporting documentation should be submitted with the PA request.

Match unit and period on the claim to the QL (e.g., "100 Grams Per 30 DAYS", "5 Pens Per 30 DAYS").
Provide NDC and starter kit documentation when the QL is NDC-specific or for starter packs set at kit/NDC level.
When QLs are derived from calculations (weight-based dosing, rounding conventions), include the calculation and source (e.g., weight, dosing schedule, CDC percentile) in the PA/supporting documentation.

Note

Prior authorization not specified in excerpt — verify plan rules

Some dispensing limits do not explicitly state PA requirements in the excerpt; verify plan-specific PA rules for the drug and member plan. Even when PA is not explicitly specified, claims exceeding QLs are subject to adjudication rules and may be denied unless prior authorization or manual override is obtained.

Always verify member-specific benefits and state-specific variations — contact insurer or review plan materials if uncertain.
If PA is not specified in the dispensing limits table, check the plan's pharmacy management rules or contact Prime Therapeutics/BCBSNM for operational guidance.

Documentation Required

Documentation required for prior authorization requests

When requesting quantities beyond published dispensing limits, submit a prior authorization with clinical justification and required documentation. Required documentation includes dosing regimen, patient weight (for weight-based products), NDC/kit identifiers (for starter kits), and cumulative usage across agents when limits are cumulative.

For antihemophilic/antihemophilic factor products: document patient weight and number of doses to justify vial/mL requests.
For cumulative topical limits: indicate total grams or mLs used across formulations and provide rationale.
For insulin/pen/pen-needle requests: document equivalency/quantity conversions and show how requested units align with listed pens or mL limits.
Include brand/generic designation and NDC(s) when relevant to demonstrate alignment with NDC-set QLs.

Denial Risk

Denial risk and member financial responsibility

Operational notes and denial risk: dispensing quantities exceeding the listed per-period or per-Rx limits (including per-Rx vial/pen caps, starter kits, and cumulative class limits) may be denied at claim adjudication. Members may be financially responsible for quantities above the plan limit if coverage is not approved.

Example denial/financial responsibility risk if prescribed quantity exceeds QL and no PA/override is obtained.
Example agent-specific overage risks: apremilast (example QL), Elyxyb (bottle limits), Cequa (vial limits), insulin pens and syringes (per-period cumulative caps).
Cumulative QL enforcement examples: oral triptans (18 tablets/30 days across agents), topical cumulative grams per period, and injectable cumulative vial counts.

Billing Rule

Quantity conversions and equivalency

Quantity conversions and equivalency: when limits are expressed in different unit types (e.g., pens, mLs, syringes, blisters, cartridges), providers must calculate and document the equivalency used to request coverage (for example, 15 mLs = 5 pens = 1 box; 60 blisters = 1 inhaler = 60 doses).

Provide conversion math and reference (product carton contents or manufacturer labeling) when submitting a PA.
Ensure claim line unit matches the QL unit (if QL is in "pens" submit claim as pens or document conversion to mL with supporting rationale).

Note

PROVIDER ACTIONS (summary)

Operational provider actions checklist: verify plan-specific limits and PA rules; ensure claim quantities align with QL unit/period; include NDCs and starter kit identifiers when required; document cumulative use across agents when limits are cumulative; provide weight/dosing calculations for weight-dependent products; submit PA where required and be prepared for claim adjudication enforcement.

Verify member plan benefits and state-specific variations before dispensing.
Match claim quantity/unit/period to the published QL.
Attach supporting clinical documentation and calculations for derived QLs.
Submit PA for quantities beyond listed limits and for requests that rely on cumulative allowances across agents.

ImplicationSwitching strengths does not reset the shared quantity limit — totals are summed at adjudication

inv-104: Quantity of medication allowed per specified time period

DefinitionQuantity of medication allowed per specified time period (e.g., '30 Tablets Per 30 DAYS')

ApplicationEach product entry lists the allowed unit and the time window (per Rx or per 28/30/90/180/365 days)

EnforcementClaims exceeding the specified per-period amount may be denied or require prior authorization

inv-105: QL / Dispensing Limit

TermQL / Dispensing Limit — maximum quantity of a specific drug formulation allowed per stated time period

UnitsExamples include tablets, mLs, grams, pens, syringes, inhalers, patches

EffectCoverage is limited to the listed QL; exceeding it may trigger prior authorization or member financial responsibility

inv-106: Cumulative across agents

DefinitionCumulative across agents: quantity limits that apply across multiple formulations/agents of the same active ingredient (counts combined toward the same QL)

ExamplesTopical corticosteroids and diclofenac patches have cumulative QLs across formulations/agents

Claim impactTotal dispensed amount across agents is used to enforce the cap at adjudication

inv-107: Quantity limit cumulative across agents

DefinitionQuantity limit cumulative across agents: some entries note limits are cumulative across agents or strengths, meaning total dispensed quantity across related products counts toward the cap

ExamplesRebif syringes cumulative across strengths; insulin syringes/pen needles cumulative at 300 units/30 days

Provider actionDocument product/strength on claims so cumulative limits can be tracked correctly

inv-110: abaloparatide pen-injector (Tymlos)

Productabaloparatide pen-injector (Tymlos) 3120 mcg/1.56 mL

Dispensing Limit1.56 mLs per 30 days (1 injection)

DesignationListed as B (brand)

inv-111: abatacept prefilled syringes (Orencia)

Productabatacept prefilled syringes (Orencia)

Dispensing Limit4 syringes per 28 days

Package equivalencyExample: 1.6 mLs = 4 syringes = 1 box (per source)

inv-112: abemaciclib tabs (Verzenio)

Productabemaciclib tabs (Verzenio)

Dispensing Limit60 tablets per 30 days

DesignationListed as B (brand)

inv-113: acyclovir buccal tab (Sitavig)

Productacyclovir buccal tab (Sitavig)

Dispensing Limit2 tablets per 180 days

DesignationListed as B (brand)

inv-114: adalimumab auto-injector kit (Humira)

Productadalimumab auto-injector kit (Humira) 40 mg/0.4 mL and biosimilars

Typical limits2 pens or 2 syringes per 28 days for many auto-injector kits; some starter kits limited to 1 kit per 180 days

Multiple presentationsEach biosimilar/preparation is assigned its own dispensing limit as listed (e.g., Adalimumab-Adbm = 2 syringes/28 days)

inv-115: adalimumab-aacf prefilled syringe kit (Idacio)

Product examplesadalimumab-aacf prefilled syringe kit (Idacio) — 1 kit per 28 days; adalimumab-adbm prefilled syringe kit — 2 syringes per 28 days

Coverage noteFormulation- and pack-specific limits apply (see individual entries)

DesignationEntries list B/BG designations per product

inv-116: adalimumab-adbm prefilled syringe kit

Productadalimumab-adbm prefilled syringe kit 40 mg/0.4 mL (Adalimumab-Adbm)

Dispensing Limit2 syringes per 28 days (40 mg/0.4 mL)

Alternate pack40 mg/0.8 mL presentation limited to 1 kit per 28 days

inv-117: albuterol sulfate Proair Respiclick

Productalbuterol sulfate Proair Respiclick (aerosol powder) 108 mcg/act

Dispensing Limit2 inhalers per 30 days

NoteAlbuterol inhaler entries commonly limited to 2 inhalers/30 days; nebulizer solutions have separate mL/vial limits

inv-118: almotriptan malate tab (oral triptans)

Product classAlmotriptan malate (oral triptans)

Dispensing Limit18 tablets per 30 days (cumulative across oral triptans)

DesignationListed as G (generic) in source for almotriptan strengths

inv-119: alpelisib (various packs)

Productalpelisib (various packs)

Dispensing Limit28 or 56 tablets per 28 days depending on pack/configuration

DesignationListed as B (brand) in source entries

inv-120: alprostadil for inj (Caverject)

Productalprostadil for injection (Caverject and related kits)

Dispensing Limit8 doses per 30 days (examples for 20–40 mcg formulations)

Kit variantsSome kits have limits expressed as doses or kits per 30 days (e.g., Edex = 4 kits per 30 days)

inv-121: ambrisentan 5 mg (Letairis)

Productambrisentan 5 mg (Letairis)

Dispensing Limit30 tablets per 30 days

DesignationListed as BG in source

inv-122: amcinonide 0.1% (cream/lotion/ointment)

Productamcinonide 0.1% (cream/lotion/ointment)

Dispensing Limit100 grams per 30 days (100/30 cumulative across agents)

Cumulative ruleLimit is cumulative across specified topical agents

inv-123: amifampridine phosphate 10 mg (Firdapse)

Productamifampridine phosphate 10 mg (Firdapse)

Dispensing Limit300 tablets per 30 days

DesignationListed as B (brand)

inv-124: amikacin liposome inhalation (Arikayce)

Productamikacin liposome inhalation (Arikayce) 590 mg/8.4 mL

Dispensing Limit28 vials per 28 days

DesignationListed as B (brand)

inv-125: amlodipine benzoate oral suspension (Katerzia)

Productamlodipine benzoate oral suspension (Katerzia) 1 mg/mL

Dispensing Limit300 mLs per 30 days

DesignationListed as B (brand)

inv-126: amlodipine besylate oral solution (Norliqva)

Productamlodipine besylate oral solution (Norliqva) 1 mg/mL

Dispensing Limit300 mLs per 30 days

DesignationListed as B (brand)

inv-127: amphetamine extended release suspension (Dyanavel Xr)

Productamphetamine extended release suspension (Dyanavel Xr) 2.5 mg/mL

Dispensing Limit240 mLs per 30 days

DesignationListed as B (brand)